# Enveda

> AI drug discovery built on nature's chemistry.

## Why it is interesting

Enveda links large-scale biological data and AI with a clinical pipeline, making its execution measurable through trial progress rather than discovery claims alone.

## Profile

- **Latest funding:** Series E — $311M (September 23, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $311M
- **Stage:** growth
- **Status:** private
- **Industries:** N/A
- **Coverage:** stub
- **Last updated:** 2026-09-25
- **Latest funding investors:** Catalio Capital Management, Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital

## Funding history

- Series E · $311M · September 23, 2026
  Source: https://enveda.com/news/enveda-raises-311-million/

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 25, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/enveda